Regeneron presents encouraging phase 2 results for high-dose aflibercept 8 mg in wet age-related macular degeneration at angiogenesis meeting

Tarrytown, n.y., feb. 11, 2022 /prnewswire/ --  trial met primary safety endpoint and no new safety signals seen through week 44 results favored aflibercept 8 mg in visual acuity, drying and other anatomical measures through week 44 phase 3 results in wet age-related macular degeneration and diabetic macular edema expected in the second half of 2022 regeneron pharmaceuticals, inc. (nasdaq: regn) today announced results from its phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of eylea® (aflibercept) injection in patients with wet age-related macular degeneration (wet amd).
REGN Ratings Summary
REGN Quant Ranking